Search research articles
Contact Us
Filters
Showing results (31-40 of 65) with videos related to
Page
of 7
Sort By:
Pediatric Blood & Cancer
|
November 3, 2016
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis
Robert J Arceci, Carl E Allen, Ira J Dunkel, et al.
Blood
|
May 4, 2018
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease
Oussama Abla, Eric Jacobsen, Jennifer Picarsic, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 23, 2026
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Jennifer L Crombie, Austin I Kim, Robert Redd, et al.
Blood Advances
|
January 8, 2024
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
Marco Herling, Claire Dearden, Francesco Zaja, et al.
Haematologica
|
July 20, 2023
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors
Steven Le Gouill, Monika Długosz-Danecka, Simon Rule, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 27, 2015
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma
Yi-Bin Chen, Shuli Li, David C Fisher, et al.
Haematologica
|
May 7, 2013
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
Jennifer R Brown, Bradley Messmer, Lillian Werner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
Owen A O'Connor, Barbara Pro, Lauren Pinter-Brown, et al.
Blood
|
March 6, 2012
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
Myron S Czuczman, Luis Fayad, Vincent Delwail, et al.
JACC. Heart Failure
|
July 28, 2022
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines
Carlos A Gongora, Zsofia D Drobni, Thiago Quinaglia Araujo Costa Silva, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 65) with videos related to
Sort By:
Page
of 7
Pediatric Blood & Cancer
|
November 3, 2016
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis
Robert J Arceci, Carl E Allen, Ira J Dunkel, et al.
Blood
|
May 4, 2018
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease
Oussama Abla, Eric Jacobsen, Jennifer Picarsic, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 23, 2026
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Jennifer L Crombie, Austin I Kim, Robert Redd, et al.
Blood Advances
|
January 8, 2024
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
Marco Herling, Claire Dearden, Francesco Zaja, et al.
Haematologica
|
July 20, 2023
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors
Steven Le Gouill, Monika Długosz-Danecka, Simon Rule, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 27, 2015
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma
Yi-Bin Chen, Shuli Li, David C Fisher, et al.
Haematologica
|
May 7, 2013
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
Jennifer R Brown, Bradley Messmer, Lillian Werner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
Owen A O'Connor, Barbara Pro, Lauren Pinter-Brown, et al.
Blood
|
March 6, 2012
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
Myron S Czuczman, Luis Fayad, Vincent Delwail, et al.
JACC. Heart Failure
|
July 28, 2022
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines
Carlos A Gongora, Zsofia D Drobni, Thiago Quinaglia Araujo Costa Silva, et al.
Page
of 7